{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Zymeworks, Inc.
Zymeworks, Inc. Hits New 52-Week High at $19.98
Zymeworks, Inc. has achieved a new 52-week high, reflecting its strong performance with a 79.73% growth in net sales reported in June. Over the past year, the company has outperformed the S&P 500, generating returns of 41.46%, while maintaining a market capitalization of USD 1,150 million.
Zymeworks, Inc. Hits New 52-Week High of USD 19.50
Zymeworks, Inc. has achieved a new 52-week high, reflecting strong operational momentum and a 79.73% increase in net sales over the past year. The company has outperformed the S&P 500 and demonstrated resilience despite losses, supported by improved financial results and reduced raw material costs.
Is Zymeworks, Inc. technically bullish or bearish?
As of August 25, 2025, Zymeworks, Inc. has a bullish technical trend supported by strong indicators, outperforming the S&P 500 with a 17.37% return over the past month and 31.71% over the past year.
Is Zymeworks, Inc. overvalued or undervalued?
As of March 6, 2024, Zymeworks, Inc. is considered overvalued with a risky valuation grade, reflected by a price-to-book ratio of 2.72, an EV to EBITDA of -6.53, a ROCE of -171.02%, and a year-to-date return of -14.82%, contrasting sharply with its peers and the S&P 500's performance.
Is Zymeworks, Inc. technically bullish or bearish?
As of June 10, 2025, Zymeworks, Inc. shows a mildly bullish trend based on weekly and monthly indicators, despite some caution from daily moving averages.
What does Zymeworks, Inc. do?
Zymeworks, Inc. is a clinical-stage biopharmaceutical company focused on developing bio-therapeutics for cancer treatment, with a market cap of approximately $859.90 million. As of March 2025, it reported net sales of $27 million and a net loss of $23 million.
How big is Zymeworks, Inc.?
As of Jun 18, Zymeworks, Inc. has a market capitalization of 859.90 million and reported net sales of 93.38 million, with a net profit loss of 113.69 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
